The Pharma Data

JANUARY 19, 2021

TC-210 is currently in a Phase I/II trial for mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Syros Pharmaceuticals – Syros announced its IPO on January 20, offering 5.4 million shares of common stock at $14 per share, to raise $75.6

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

JUNE 11, 2025

The expanded agreement, which now stretches the collaboration through at least 2028, marks a new chapter in the two organizations’ efforts to harness cutting-edge genomic research, high-throughput screening platforms, and translational science to deliver precision medicines that could alter the course of chronic cardiovascular diseases.

Drug Research 40

Drug Research Research Small Molecule Drugs 40

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Pfizer announced several key advances in its efforts to protect humankind from the COVID-19 pandemic and prepare the pharmaceutical industry to better respond to future global health crises.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52